MX2018005950A - Control exogeno de expresion genica en mamiferos a traves de modulacion mediada por aptameros de poliadenilacion. - Google Patents
Control exogeno de expresion genica en mamiferos a traves de modulacion mediada por aptameros de poliadenilacion.Info
- Publication number
- MX2018005950A MX2018005950A MX2018005950A MX2018005950A MX2018005950A MX 2018005950 A MX2018005950 A MX 2018005950A MX 2018005950 A MX2018005950 A MX 2018005950A MX 2018005950 A MX2018005950 A MX 2018005950A MX 2018005950 A MX2018005950 A MX 2018005950A
- Authority
- MX
- Mexico
- Prior art keywords
- transcription
- aptameros
- polyadenilation
- exogenic
- mammals
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title abstract 4
- 241000124008 Mammalia Species 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 239000003446 ligand Substances 0.000 abstract 5
- 230000035897 transcription Effects 0.000 abstract 4
- 238000013518 transcription Methods 0.000 abstract 4
- 108091023037 Aptamer Proteins 0.000 abstract 3
- 108020003589 5' Untranslated Regions Proteins 0.000 abstract 2
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000011144 upstream manufacturing Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Las modalidades de la descripción se refieren al uso de construcciones de expresión en las cuales al menos una señal de polyA está incrustada corriente arriba de una transcripción expresable, tal como, por ejemplo, dentro de un 5´ UTR para la transcripción. En determinadas modalidades, la señal de polyA está comprendida dentro de un aptámero de unión al ligando, y la unión del ligando al aptámero, o la falta de esta, indica el resultado para la transcripción expresable. En modalidades específicas, la ausencia del ligando provoca que la transcripción expresada que tiene un polyA en su 5´ UTR se exprese, pero que después se degrade, mientras que la presencia del ligando provoca la inhibición de la degradación tras la expresión de la transcripción expresable. Puede haber más de un aptámero de unión al ligando presente en la misma construcción de expresión.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562254435P | 2015-11-12 | 2015-11-12 | |
| PCT/US2016/061665 WO2017083747A1 (en) | 2015-11-12 | 2016-11-11 | Exogenous control of mammalian gene expression through aptamer-mediated modulation of polyadenylation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018005950A true MX2018005950A (es) | 2018-11-09 |
Family
ID=58696115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018005950A MX2018005950A (es) | 2015-11-12 | 2016-11-11 | Control exogeno de expresion genica en mamiferos a traves de modulacion mediada por aptameros de poliadenilacion. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20180327747A1 (es) |
| EP (1) | EP3374506B1 (es) |
| JP (2) | JP7100361B2 (es) |
| KR (1) | KR20180083347A (es) |
| CN (1) | CN108350451A (es) |
| AU (1) | AU2016353339B2 (es) |
| CA (1) | CA3005224A1 (es) |
| ES (1) | ES2969015T3 (es) |
| MX (1) | MX2018005950A (es) |
| RU (1) | RU2769991C2 (es) |
| WO (1) | WO2017083747A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7100361B2 (ja) | 2015-11-12 | 2022-07-13 | ベイラー カレッジ オブ メディスン | ポリアデニル化のアプタマー介在型調節を通じた哺乳類遺伝子発現の外因的制御 |
| MX2022002390A (es) * | 2019-08-30 | 2022-05-13 | Baylor College Medicine | Sistema para regular la expresion genica. |
| US20230322842A1 (en) * | 2020-04-14 | 2023-10-12 | Sumitomo Chemical Company, Limited | Composition containing nucleic acid oligomer |
| IL310702A (en) | 2021-08-11 | 2024-04-01 | Sana Biotechnology Inc | Inducible systems for altering gene expression in hypoimmunogenic cells |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1092777A1 (en) * | 1999-10-15 | 2001-04-18 | Aventis Pharma S.A. | Self-cleaving RNA sequences and their use for the control of protein synthesis. |
| WO2002062949A2 (en) * | 2000-10-20 | 2002-08-15 | Canji, Inc | Aptamer-mediated regulation of gene expression |
| AU2003288906C1 (en) * | 2002-09-20 | 2010-12-09 | Yale University | Riboswitches, methods for their use, and compositions for use with riboswitches. |
| AU2003282538A1 (en) * | 2002-10-10 | 2004-05-04 | Oxford Biomedica (Uk) Limited | Gene regulation with aptamer and modulator complexes for gene therapy |
| CA2545697C (en) | 2003-11-14 | 2016-12-20 | Richard Mulligan | Self-cleaving ribozymes and uses thereof |
| EP2247731A2 (en) * | 2008-02-11 | 2010-11-10 | Duke University | Aptamer inhibitors of osteopontin and methods of use thereof |
| EP2430161A1 (en) * | 2009-05-15 | 2012-03-21 | Yale University | Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches |
| US8680017B2 (en) * | 2010-02-13 | 2014-03-25 | Gregory Francis Lopreato | Lariat aptamer: aptamer candidate exclusion by nuclease digestion |
| US20160130585A1 (en) * | 2013-05-28 | 2016-05-12 | The Johns Hopkins University | Aptamers for the treatment of sickle cell disease |
| CN104651501A (zh) * | 2015-01-30 | 2015-05-27 | 湖南大学 | 裂开型激活式核酸适配体诊疗探针及其应用 |
| JP7100361B2 (ja) | 2015-11-12 | 2022-07-13 | ベイラー カレッジ オブ メディスン | ポリアデニル化のアプタマー介在型調節を通じた哺乳類遺伝子発現の外因的制御 |
| EP3411081A4 (en) * | 2016-02-02 | 2019-12-11 | Meiragtx UK II Limited | REGULATION OF GENE EXPRESSION BY APTAM-MODULATED POLYADENYLATION |
| MX2022002390A (es) | 2019-08-30 | 2022-05-13 | Baylor College Medicine | Sistema para regular la expresion genica. |
-
2016
- 2016-11-11 JP JP2018524382A patent/JP7100361B2/ja active Active
- 2016-11-11 CA CA3005224A patent/CA3005224A1/en active Pending
- 2016-11-11 ES ES16865151T patent/ES2969015T3/es active Active
- 2016-11-11 WO PCT/US2016/061665 patent/WO2017083747A1/en not_active Ceased
- 2016-11-11 AU AU2016353339A patent/AU2016353339B2/en active Active
- 2016-11-11 CN CN201680066010.2A patent/CN108350451A/zh active Pending
- 2016-11-11 EP EP16865151.1A patent/EP3374506B1/en active Active
- 2016-11-11 US US15/775,804 patent/US20180327747A1/en not_active Abandoned
- 2016-11-11 KR KR1020187015503A patent/KR20180083347A/ko active Pending
- 2016-11-11 MX MX2018005950A patent/MX2018005950A/es unknown
- 2016-11-11 RU RU2018121041A patent/RU2769991C2/ru active
-
2021
- 2021-01-08 US US17/144,456 patent/US12215323B2/en active Active
-
2022
- 2022-01-07 JP JP2022001604A patent/JP2022062019A/ja active Pending
-
2024
- 2024-11-14 US US18/948,183 patent/US20250066796A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20180327747A1 (en) | 2018-11-15 |
| CN108350451A (zh) | 2018-07-31 |
| EP3374506A4 (en) | 2019-04-17 |
| HK1258245A1 (en) | 2019-11-08 |
| WO2017083747A1 (en) | 2017-05-18 |
| RU2769991C2 (ru) | 2022-04-12 |
| AU2016353339B2 (en) | 2023-06-01 |
| BR112018009621A8 (pt) | 2019-02-26 |
| US20250066796A1 (en) | 2025-02-27 |
| JP2022062019A (ja) | 2022-04-19 |
| ES2969015T3 (es) | 2024-05-16 |
| JP7100361B2 (ja) | 2022-07-13 |
| BR112018009621A2 (pt) | 2018-11-06 |
| US20210310003A1 (en) | 2021-10-07 |
| RU2018121041A3 (es) | 2020-04-27 |
| KR20180083347A (ko) | 2018-07-20 |
| EP3374506B1 (en) | 2023-12-27 |
| CA3005224A1 (en) | 2017-05-18 |
| US12215323B2 (en) | 2025-02-04 |
| RU2018121041A (ru) | 2019-12-16 |
| AU2016353339A1 (en) | 2018-06-07 |
| JP2018533955A (ja) | 2018-11-22 |
| EP3374506A1 (en) | 2018-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501262A1 (en) | Modified guide rnas | |
| PH12020552100A1 (en) | Modified guide rnas for gene editing | |
| MY197415A (en) | Functional expression of monooxygenase and methods of use | |
| MX2018004160A (es) | Secuencias 3´ utr para estabilización de arn. | |
| DOP2013000216A (es) | Modulacion de la expresion del transductor de señales y activador de la transcripcion 3 (stat3) | |
| EP3814495C0 (en) | BIOREACTOR FOR IN VITRO TRANSCRIPTION OF RNA | |
| PE20210114A1 (es) | .COMPOSICIONES DE ARNi CONTRA EL ANGIOTENSINOGENO (AGT) Y METODOS PARA SU USO | |
| CO2017007335A2 (es) | Supresión del gen de la huntingtina inducida por la arni | |
| MX2018012880A (es) | Metodos para proporcionar arn de hebra sencilla. | |
| UA117008C2 (uk) | IN VITRO ТРАНСКРИБОВАНА мРНК ТА КОМПОЗИЦІЯ, ЩО ЇЇ МІСТИТЬ, ДЛЯ ЗАСТОСУВАННЯ В ЛІКУВАННІ МУКОВІСЦИДОЗУ В ССАВЦЯ | |
| MX2017015373A (es) | COMPOSICIONES Y MíTODOS PARA LA DEGRADACIíN DE PROTEíNAS MAL PLEGADAS. | |
| PE20130213A1 (es) | Marcadores predictivos utiles en el tratamiento del sindrome fragil x (fxs) | |
| AR089830A1 (es) | Acido nucleico, vector de expresion, celula bacteriana, celula de planta de citrus y metodo de expresion de un acido nucleico exogeno en la planta de citrus | |
| PE20210921A1 (es) | Agentes arni como inhibidores de la transcripcion de la serpina 1 y composiciones que los comprenden | |
| MX2018005950A (es) | Control exogeno de expresion genica en mamiferos a traves de modulacion mediada por aptameros de poliadenilacion. | |
| BR112016002524A2 (pt) | alvos moleculares para a prevenção e/ou tratamento de fibrose, cicatrizes hipertróficas e quelóides | |
| BR112018070249A2 (pt) | sistema promotor de u6 modificada para expressão específica de tecido | |
| PE20171673A1 (es) | Recubrimiento resistente al cuarteado y metodo del mismo | |
| CL2019001397A1 (es) | Estabilidad mejorada de composiciones que contienen inhibidor de la ureasa. | |
| CL2016003140A1 (es) | Sistema de expresión génica | |
| CO2018000171A2 (es) | Metodos de purificacion y/o inactividad viral | |
| CR20110361A (es) | Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, su preparación y su aplicación en terapeutica como activadores de hif | |
| CA2986376C (en) | Poxvirus-derived promoter, and vector comprising same | |
| UY34915A (es) | Purificación de inhibidor de proteasa alfa1 derivado de cultivo celular | |
| AR086030A1 (es) | Metodos y dispositivos para amplificar acidos nucleicos |